- Home
- HSPO vs ABP Comparison
HSPO vs ABP Comparison
Compare HSPO & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSPO
- ABP
- Stock Information
- Founded
- HSPO 2014
- ABP 2004
- Country
- HSPO United States
- ABP United States
- Employees
- HSPO N/A
- ABP N/A
- Industry
- HSPO Blank Checks
- ABP Biotechnology: Pharmaceutical Preparations
- Sector
- HSPO Finance
- ABP Health Care
- Exchange
- HSPO Nasdaq
- ABP Nasdaq
- Market Cap
- HSPO 92.0M
- ABP 76.2M
- IPO Year
- HSPO 2022
- ABP N/A
- Fundamental
- Price
- HSPO $11.65
- ABP $0.84
- Analyst Decision
- HSPO
- ABP
- Analyst Count
- HSPO 0
- ABP 0
- Target Price
- HSPO N/A
- ABP N/A
- AVG Volume (30 Days)
- HSPO 3.5K
- ABP 39.1K
- Earning Date
- HSPO 01-01-0001
- ABP 03-07-2025
- Dividend Yield
- HSPO N/A
- ABP N/A
- EPS Growth
- HSPO 2.63
- ABP N/A
- EPS
- HSPO 0.28
- ABP N/A
- Revenue
- HSPO N/A
- ABP $230,000.00
- Revenue This Year
- HSPO N/A
- ABP N/A
- Revenue Next Year
- HSPO N/A
- ABP N/A
- P/E Ratio
- HSPO $41.35
- ABP N/A
- Revenue Growth
- HSPO N/A
- ABP N/A
- 52 Week Low
- HSPO $10.80
- ABP $0.80
- 52 Week High
- HSPO $12.41
- ABP $13.00
- Technical
- Relative Strength Index (RSI)
- HSPO 48.83
- ABP N/A
- Support Level
- HSPO $11.70
- ABP N/A
- Resistance Level
- HSPO $11.78
- ABP N/A
- Average True Range (ATR)
- HSPO 0.07
- ABP 0.00
- MACD
- HSPO -0.02
- ABP 0.00
- Stochastic Oscillator
- HSPO 0.00
- ABP 0.00
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms, The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with global pharmaceutical and research institutions.